COVID-19 Vaccination and Thromboembolic Events: A Review of Current Research

Strategic Insights -

A new study on gene therapy has highlighted the association between COVID-19 vaccination and thromboembolic events, particularly with adenoviral vector-based vaccines. Researchers from the Department of Cardiology underscored the rare occurrence of venous thromboembolism, arterial thromboembolism, and vaccine-induced thrombotic thrombocytopenia following COVID-19 vaccination. However, the overwhelming majority of evidence supports the continued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality.

Key Takeaways:

  • The association between COVID-19 vaccination and thromboembolic events has garnered significant research attention, particularly with adenoviral vector-based vaccines.
  • Researchers have documented rare renal complications such as acute kidney injury and thrombotic microangiopathy, broadening the spectrum of potential vaccine-associated thrombotic manifestations.
  • Current guidelines emphasize early detection, individualized risk assessment, and use of anticoagulation therapy to mitigate risks.
  • Ongoing research is essential to further refine preventive and therapeutic strategies, particularly for at-risk populations.
  • A recent comparative study confirmed that mRNA-based vaccines are associated with a significantly lower risk of serious thrombotic events compared to adenoviral vector platforms.
  • The study underscores the importance of early detection and risk assessment to mitigate the risk of thromboembolic events.
  • Researchers emphasize the need for further research to identify predictors of thromboembolic events in vaccinated individuals.
  • The study highlights the importance of monitoring for rare but serious complications, such as thrombotic microangiopathy.
  • The study underscores the need for coordination between healthcare providers and researchers to develop effective strategies for preventing and treating thromboembolic events.

Statistics:

  • The occurrence of venous thromboembolism following COVID-19 vaccination is extremely rare, occurring in approximately 6.7 cases per million vaccinated individuals (Source: Update on Thromboembolic Events After Vaccination Against COVID-19).
  • Arterial thromboembolism is also rare, occurring in approximately 2.3 cases per million vaccinated individuals (Source: Update on Thromboembolic Events After Vaccination Against COVID-19).
  • Vaccine-induced thrombotic thrombocytopenia is a rare but serious complication, occurring in approximately 2.1 cases per million vaccinated individuals (Source: Update on Thromboembolic Events After Vaccination Against COVID-19).

Sources:

  • Update on Thromboembolic Events After Vaccination Against COVID-19. Vaccines, 2025, 13(8), 833. (Vaccines - http://www.mdpi.com/journal/vaccines).
  • NewsRx. Research from Athens Broadens Understanding of Gene Therapy (Update on Thromboembolic Events After Vaccination Against COVID-19). Gene Therapy Weekly. September 11, 2025; p 215.